Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?
Identifieur interne : 004A28 ( Main/Curation ); précédent : 004A27; suivant : 004A29Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?
Auteurs : Annick Mouatt-Prigent [France] ; Yves Agid [France] ; Etienne C. Hirsch [France]Source :
- Brain Research [ 0006-8993 ] ; 1994.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Binding protein, Calbindin 2, Calcium, Calcium (metabolism), Calcium binding protein, Calretinin, Cell Death, Degeneration, Dopamine, Dopaminergic neuron, Human, Humans, Immunohistochemistry, Mesencephalon, Nerve Degeneration, Neuroprotective agent, Parkinson Disease (enzymology), Parkinson Disease (pathology), Parkinson disease, Parkinson's disease, S100 Calcium Binding Protein G (analysis), S100 Calcium Binding Protein G (physiology), Substantia Nigra (chemistry), Substantia Nigra (pathology), Tyrosine 3-Monooxygenase (analysis), Tyrosine hydroxylase.
- MESH :
- chemical , analysis : S100 Calcium Binding Protein G, Tyrosine 3-Monooxygenase.
- chemical , metabolism : Calcium.
- chemical , physiology : S100 Calcium Binding Protein G.
- chemical : Calbindin 2, Dopamine.
- chemistry : Substantia Nigra.
- enzymology : Parkinson Disease.
- pathology : Parkinson Disease, Substantia Nigra.
- Aged, Aged, 80 and over, Cell Death, Humans, Immunohistochemistry, Nerve Degeneration.
Abstract
Abstract: Parkinson's disease (PD) is characterized by a heterogeneous loss of dopaminergic neurons in the human mesencephalon affecting mainly the substantia nigra pars compacta (SNpc) and to a lesser extent the other dopaminergic cell groups. A rise in intracellular calcium concentrations represents one of the final events leading to nerve cell death. Calbindin D28k, a protein capable of buffering intracellular calcium concentrations is present in the dopaminergic neurons that are selectively preserved in PD but not in those that degenerate. To determine whether other calcium-binding proteins also represent putative protective factors of dopaminergic neurons in PD, we analyzed immunohistochemically the distribution of calretinin-containing (CR+) neurons, in the human mesencephalon of three control subjects and four patients with PD. No significant differences were observed between the number of CR+ neurons in the two subject groups. Sequential double immunostaining for calretinin and tyrosine hydroxylase showed a variable proportion of CR+ neurons among dopaminergic neurons: moderate co-localization was found in catecholaminergic cell group A8 and in the dorsal part of the ventral tegmental area (VTA) and low co-localization in the SNpc, the ventral part of the VTA and the central gray substance. This indicates that calretinin may only protect some dopaminergic neurons against degeneration in PD. Yet, in the SNpc a selective preservation of CR+ dopaminergic neurons was observed, suggesting a neuroprotective role in some dopaminergic cell groups only.
Url:
DOI: 10.1016/0006-8993(94)90511-8
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A75
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001A73
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001A78
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005382
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001915
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001732
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001805
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005449
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001652
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001611
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001611
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001C75
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001C75
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001C75
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005265
Links to Exploration step
ISTEX:28498A4DCDF24F2114BDDFAB7D43925455B0BFA8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?</title><author><name sortKey="Mouatt Prigent, Annick" sort="Mouatt Prigent, Annick" uniqKey="Mouatt Prigent A" first="Annick" last="Mouatt-Prigent">Annick Mouatt-Prigent</name></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:28498A4DCDF24F2114BDDFAB7D43925455B0BFA8</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1016/0006-8993(94)90511-8</idno><idno type="url">https://api.istex.fr/document/28498A4DCDF24F2114BDDFAB7D43925455B0BFA8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A75</idno><idno type="wicri:Area/Istex/Curation">001A73</idno><idno type="wicri:Area/Istex/Checkpoint">001A78</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A78</idno><idno type="wicri:doubleKey">0006-8993:1994:Mouatt Prigent A:does:the:calcium</idno><idno type="wicri:Area/Main/Merge">005382</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:95-0071900</idno><idno type="wicri:Area/PascalFrancis/Corpus">001915</idno><idno type="wicri:Area/PascalFrancis/Curation">001732</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001805</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001805</idno><idno type="wicri:doubleKey">0006-8993:1994:Mouatt Prigent A:does:the:calcium</idno><idno type="wicri:Area/Main/Merge">005449</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:7704619</idno><idno type="wicri:Area/PubMed/Corpus">001652</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001652</idno><idno type="wicri:Area/PubMed/Curation">001611</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001611</idno><idno type="wicri:Area/PubMed/Checkpoint">001611</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001611</idno><idno type="wicri:Area/Ncbi/Merge">001C75</idno><idno type="wicri:Area/Ncbi/Curation">001C75</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C75</idno><idno type="wicri:doubleKey">0006-8993:1994:Mouatt Prigent A:does:the:calcium</idno><idno type="wicri:Area/Main/Merge">005265</idno><idno type="wicri:Area/Main/Curation">004A28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?</title><author><name sortKey="Mouatt Prigent, Annick" sort="Mouatt Prigent, Annick" uniqKey="Mouatt Prigent A" first="Annick" last="Mouatt-Prigent">Annick Mouatt-Prigent</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hoˆpital de la Salpêtrière, 47 boulevard de l'Hoˆpital, 75013 Paris </wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris </settlement></placeName></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hoˆpital de la Salpêtrière, 47 boulevard de l'Hoˆpital, 75013 Paris </wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris </settlement></placeName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hoˆpital de la Salpêtrière, 47 boulevard de l'Hoˆpital, 75013 Paris </wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris </settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994">1994</date><biblScope unit="volume">668</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="62">62</biblScope><biblScope unit="page" to="70">70</biblScope></imprint><idno type="ISSN">0006-8993</idno></series><idno type="istex">28498A4DCDF24F2114BDDFAB7D43925455B0BFA8</idno><idno type="DOI">10.1016/0006-8993(94)90511-8</idno><idno type="PII">0006-8993(94)90511-8</idno><idno type="ArticleID">94905118</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Binding protein</term><term>Calbindin 2</term><term>Calcium</term><term>Calcium (metabolism)</term><term>Calcium binding protein</term><term>Calretinin</term><term>Cell Death</term><term>Degeneration</term><term>Dopamine</term><term>Dopaminergic neuron</term><term>Human</term><term>Humans</term><term>Immunohistochemistry</term><term>Mesencephalon</term><term>Nerve Degeneration</term><term>Neuroprotective agent</term><term>Parkinson Disease (enzymology)</term><term>Parkinson Disease (pathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>S100 Calcium Binding Protein G (analysis)</term><term>S100 Calcium Binding Protein G (physiology)</term><term>Substantia Nigra (chemistry)</term><term>Substantia Nigra (pathology)</term><term>Tyrosine 3-Monooxygenase (analysis)</term><term>Tyrosine hydroxylase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>S100 Calcium Binding Protein G</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Calcium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>S100 Calcium Binding Protein G</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Calbindin 2</term><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cell Death</term><term>Humans</term><term>Immunohistochemistry</term><term>Nerve Degeneration</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Calcium</term><term>Calrétinine</term><term>Dégénérescence</term><term>Homme</term><term>Neurone dopaminergique</term><term>Neuroprotecteur</term><term>Parkinson maladie</term><term>Protéine liaison</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Calcium</term><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Parkinson's disease (PD) is characterized by a heterogeneous loss of dopaminergic neurons in the human mesencephalon affecting mainly the substantia nigra pars compacta (SNpc) and to a lesser extent the other dopaminergic cell groups. A rise in intracellular calcium concentrations represents one of the final events leading to nerve cell death. Calbindin D28k, a protein capable of buffering intracellular calcium concentrations is present in the dopaminergic neurons that are selectively preserved in PD but not in those that degenerate. To determine whether other calcium-binding proteins also represent putative protective factors of dopaminergic neurons in PD, we analyzed immunohistochemically the distribution of calretinin-containing (CR+) neurons, in the human mesencephalon of three control subjects and four patients with PD. No significant differences were observed between the number of CR+ neurons in the two subject groups. Sequential double immunostaining for calretinin and tyrosine hydroxylase showed a variable proportion of CR+ neurons among dopaminergic neurons: moderate co-localization was found in catecholaminergic cell group A8 and in the dorsal part of the ventral tegmental area (VTA) and low co-localization in the SNpc, the ventral part of the VTA and the central gray substance. This indicates that calretinin may only protect some dopaminergic neurons against degeneration in PD. Yet, in the SNpc a selective preservation of CR+ dopaminergic neurons was observed, suggesting a neuroprotective role in some dopaminergic cell groups only.</div></front></TEI><double idat="0006-8993:1994:Mouatt Prigent A:does:the:calcium"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease ?</title><author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A." last="Mouatt-Prigent">A. Mouatt-Prigent</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U289</s1><s2>75013 Paris</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">95-0071900</idno><date when="1994">1994</date><idno type="stanalyst">PASCAL 95-0071900 INIST</idno><idno type="RBID">Pascal:95-0071900</idno><idno type="wicri:Area/PascalFrancis/Corpus">001915</idno><idno type="wicri:Area/PascalFrancis/Curation">001732</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001805</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001805</idno><idno type="wicri:doubleKey">0006-8993:1994:Mouatt Prigent A:does:the:calcium</idno><idno type="wicri:Area/Main/Merge">005449</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease ?</title><author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A." last="Mouatt-Prigent">A. Mouatt-Prigent</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U289</s1><s2>75013 Paris</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name></author></analytic><series><title level="j" type="main">Brain research</title><title level="j" type="abbreviated">Brain res.</title><idno type="ISSN">0006-8993</idno><imprint><date when="1994">1994</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Brain research</title><title level="j" type="abbreviated">Brain res.</title><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Binding protein</term><term>Calcium</term><term>Calretinin</term><term>Degeneration</term><term>Dopaminergic neuron</term><term>Human</term><term>Neuroprotective agent</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Calcium</term><term>Protéine liaison</term><term>Neurone dopaminergique</term><term>Dégénérescence</term><term>Neuroprotecteur</term><term>Parkinson maladie</term><term>Homme</term><term>Calrétinine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Calcium</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is characterized by a heterogeneous loss of dopaminergic neurons in the human mesencephalon affecting mainly the substantia nigra pars compacta (SNpc) and to a lesser extent the other dopaminergic cell groups. A rise in intracellular calcium concentrations represents one of the final events leading to nerve cell death. Calbindin D28k, a protein capable of buffering intracellular calcium concentrations is present in the dopaminergic neurons that are selectively preserved in PD but not in those that degenerate. To determine whether other calcium-binding proteins also represent putative protective factors of dopaminergic neurons in PD, we analyzed immunohistochemically the distribution of calretinin-containing (CR+) neurons, in the human mesencephalon of three control subjects and four patients with PD</div></front></TEI></INIST><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?</title><author><name sortKey="Mouatt Prigent, Annick" sort="Mouatt Prigent, Annick" uniqKey="Mouatt Prigent A" first="Annick" last="Mouatt-Prigent">Annick Mouatt-Prigent</name></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:28498A4DCDF24F2114BDDFAB7D43925455B0BFA8</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1016/0006-8993(94)90511-8</idno><idno type="url">https://api.istex.fr/document/28498A4DCDF24F2114BDDFAB7D43925455B0BFA8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A75</idno><idno type="wicri:Area/Istex/Curation">001A73</idno><idno type="wicri:Area/Istex/Checkpoint">001A78</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A78</idno><idno type="wicri:doubleKey">0006-8993:1994:Mouatt Prigent A:does:the:calcium</idno><idno type="wicri:Area/Main/Merge">005382</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?</title><author><name sortKey="Mouatt Prigent, Annick" sort="Mouatt Prigent, Annick" uniqKey="Mouatt Prigent A" first="Annick" last="Mouatt-Prigent">Annick Mouatt-Prigent</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hoˆpital de la Salpêtrière, 47 boulevard de l'Hoˆpital, 75013 Paris </wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris </settlement></placeName></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hoˆpital de la Salpêtrière, 47 boulevard de l'Hoˆpital, 75013 Paris </wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris </settlement></placeName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hoˆpital de la Salpêtrière, 47 boulevard de l'Hoˆpital, 75013 Paris </wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris </settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994">1994</date><biblScope unit="volume">668</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="62">62</biblScope><biblScope unit="page" to="70">70</biblScope></imprint><idno type="ISSN">0006-8993</idno></series><idno type="istex">28498A4DCDF24F2114BDDFAB7D43925455B0BFA8</idno><idno type="DOI">10.1016/0006-8993(94)90511-8</idno><idno type="PII">0006-8993(94)90511-8</idno><idno type="ArticleID">94905118</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Calcium binding protein</term><term>Human</term><term>Mesencephalon</term><term>Parkinson's disease</term><term>Tyrosine hydroxylase</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Parkinson's disease (PD) is characterized by a heterogeneous loss of dopaminergic neurons in the human mesencephalon affecting mainly the substantia nigra pars compacta (SNpc) and to a lesser extent the other dopaminergic cell groups. A rise in intracellular calcium concentrations represents one of the final events leading to nerve cell death. Calbindin D28k, a protein capable of buffering intracellular calcium concentrations is present in the dopaminergic neurons that are selectively preserved in PD but not in those that degenerate. To determine whether other calcium-binding proteins also represent putative protective factors of dopaminergic neurons in PD, we analyzed immunohistochemically the distribution of calretinin-containing (CR+) neurons, in the human mesencephalon of three control subjects and four patients with PD. No significant differences were observed between the number of CR+ neurons in the two subject groups. Sequential double immunostaining for calretinin and tyrosine hydroxylase showed a variable proportion of CR+ neurons among dopaminergic neurons: moderate co-localization was found in catecholaminergic cell group A8 and in the dorsal part of the ventral tegmental area (VTA) and low co-localization in the SNpc, the ventral part of the VTA and the central gray substance. This indicates that calretinin may only protect some dopaminergic neurons against degeneration in PD. Yet, in the SNpc a selective preservation of CR+ dopaminergic neurons was observed, suggesting a neuroprotective role in some dopaminergic cell groups only.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?</title><author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A" last="Mouatt-Prigent">A. Mouatt-Prigent</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7704619</idno><idno type="pmid">7704619</idno><idno type="wicri:Area/PubMed/Corpus">001652</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001652</idno><idno type="wicri:Area/PubMed/Curation">001611</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001611</idno><idno type="wicri:Area/PubMed/Checkpoint">001611</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001611</idno><idno type="wicri:Area/Ncbi/Merge">001C75</idno><idno type="wicri:Area/Ncbi/Curation">001C75</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C75</idno><idno type="wicri:doubleKey">0006-8993:1994:Mouatt Prigent A:does:the:calcium</idno><idno type="wicri:Area/Main/Merge">005265</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?</title><author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A" last="Mouatt-Prigent">A. Mouatt-Prigent</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name></author></analytic><series><title level="j">Brain research</title><idno type="ISSN">0006-8993</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Calbindin 2</term><term>Calcium (metabolism)</term><term>Cell Death</term><term>Dopamine</term><term>Humans</term><term>Immunohistochemistry</term><term>Nerve Degeneration</term><term>Parkinson Disease (enzymology)</term><term>Parkinson Disease (pathology)</term><term>S100 Calcium Binding Protein G (analysis)</term><term>S100 Calcium Binding Protein G (physiology)</term><term>Substantia Nigra (chemistry)</term><term>Substantia Nigra (pathology)</term><term>Tyrosine 3-Monooxygenase (analysis)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>S100 Calcium Binding Protein G</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Calcium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>S100 Calcium Binding Protein G</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Calbindin 2</term><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cell Death</term><term>Humans</term><term>Immunohistochemistry</term><term>Nerve Degeneration</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is characterized by a heterogeneous loss of dopaminergic neurons in the human mesencephalon affecting mainly the substantia nigra pars compacta (SNpc) and to a lesser extent the other dopaminergic cell groups. A rise in intracellular calcium concentrations represents one of the final events leading to nerve cell death. Calbindin D28k, a protein capable of buffering intracellular calcium concentrations is present in the dopaminergic neurons that are selectively preserved in PD but not in those that degenerate. To determine whether other calcium-binding proteins also represent putative protective factors of dopaminergic neurons in PD, we analyzed immunohistochemically the distribution of calretinin-containing (CR+) neurons, in the human mesencephalon of three control subjects and four patients with PD. No significant differences were observed between the number of CR+ neurons in the two subject groups. Sequential double immunostaining for calretinin and tyrosine hydroxylase showed a variable proportion of CR+ neurons among dopaminergic neurons: moderate co-localization was found in catecholaminergic cell group A8 and in the dorsal part of the ventral tegmental area (VTA) and low co-localization in the SNpc, the ventral part of the VTA and the central gray substance. This indicates that calretinin may only protect some dopaminergic neurons against degeneration in PD. Yet, in the SNpc a selective preservation of CR+ dopaminergic neurons was observed, suggesting a neuroprotective role in some dopaminergic cell groups only.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004A28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:28498A4DCDF24F2114BDDFAB7D43925455B0BFA8
|texte= Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?
}}
| This area was generated with Dilib version V0.6.29. |  |